1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992; 327: 669-77.
2. The acute infarction ramipril efficacy (AIRE) study investigators. Lancet 1993; 342: 821-8.
3. Hall AS, Murray GD, Ball SG . Follow-up study of patients randomly allocated ramipril or placebo for heart failure after myocardial infarction: AIRE Extension (AIREX) study. Lancet 1997; 349: 1493-7.
4. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trials of the angiotensin-converting enzyme inhibitor trandolapril in patients with left dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.
5. GISSI-3 study group: effect of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
6. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325(5): 293-302.
7. Ferrari R. Mechanisms of protective effects of angiotensin-converting enzyme inhibitors in myocardial ischaemia. ACE Inhibition and Ischaemic Heart Disease. Science Press Ltd 1999; 13-23.
8. Bauters C, Amouyel P. Assotiation between ACE genotype and coronary artery disease. Eur Heart J 1998; 19: J24-9.
9. Antony I, Lerebours G, Nitenberg A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor testinduced dilatations in coronary arteries of hypertensive patients. Circulation 1996; 94: 3115-22.
10. Anand IS, Kalra GS, Ferrari, et al. Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. Int J Card 1990; 28: 341-6.
11. Remme WJ, Bartels Gl. Antiishaemic effects of converting enzyme inhibitors: underlying mechanisms and future prospects. Eur Heart J 1995; 16(Suppl I): 87-95.
12. Arnal J-F, Dinh-Xuan A-T, Pueyo M, et al. Endotelium-derived nitrid oxide and vascular physiology. Cell Mol Life 1999; 55: 1078-87.
13. Ridker PM, Gaboury CL, Conlin PR, et al. Stimulation of plasminogen activator in vivoby infusion of angiotensin II. Evidence of potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-73.
14. Lonn EM, Yusuf S, Dzavik V, et al. Effect of ramipril and vitamine E on aterosclerosis. Circulation 2001; 103: 919-25.
15. The HOPE Study Investigators. Effect of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
16. Lai C, Onnis E, Orani E, et al. Antiischaemic activity of ACE inhibitor enalapril in normotensive patients with stable effort angina (Abstract). JACC 1987; 9: 192A.
17. Strozzi C, Cocco G, Portaluppi F, et al. Effect of captopril on the phisical work capacity of normotensive patients with stable effort angina pectoris. Cardiology 1987; 74: 226-8.
18. Thurman P, Odenthal HJ, Rietbrock N. Converting enzyme inhibition in coronary artery disease: a randomized, placebo-controlled trials with benazepril. J Cardiovasc Pharmacol 1991; 17: 718-23.
19. Efficacy of perindopril in reduction of cardiovascular events among petients with stable coronary artery disease: randomised, doubleblind, placebo-controlled, multicentre trial (the EUROPA study). The LANCET. Published online September 2003; 1-7.
20. Angiotensin-Converting-Enzyme Inhibition in Stable Coronary Artery Disease. The PEACE Trial Investigators. N Engl J Med 2004; 351: 2058-68.
Послать статью по эл. почте 
